Neoadjuvant Darovasertib in Primary Uveal Melanoma

← catalyst calendar

NCT07015190 · readout ≤ 1,534 d

Sponsored by IDEAYA Biosciences (industry) · IDYA — their whole pipeline →.

Phase

Phase 3

Status

Recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

520estimated

Sites

Countries

Australia, Austria, Belgium +18

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-01-25

actual

When the study began enrolling

Primary completion

Oct 2030

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Mar 2031

estimated

The whole study's end, after follow-up

First posted

2025-06-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-06

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Uveal Melanoma

Interventions

Drug: Darovasertib — also filed as IDE 196
Procedure: Primary Local Therapy

Primary outcomes

what the primary-completion date above is the date OF

Cohort 1: To demonstrate that the proportion of subjects with vision loss is lower for subjects in the Treatment Arm vs the Control Arm

measured Approximately 3 years

Cohort 2: To demonstrate the ability to salvage the eye and prevent enucleation in the Treatment Arm

measured Approximately 2 years

Permalink · IDYA's whole pipeline · Catalyst calendar · Every registered study · What changed